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Abstract
Purpose Body weight and composition play a role in cancer
etiology, prognosis, and treatment response. Therefore, we
analyzed the weight, body composition changes, and out-
come in patients treated with temsirolimus, an mTor inhibitor
that has weight loss as one of its side effects.
Patients and methods Sixteen patients with advanced solid
tumors treated with temsirolimus were studied; body com-
position was evaluated utilizing computerized tomography
images. Sarcopenia was defined as skeletal muscle index
lower than 38.5 cm2/m2 for women and 52.4 cm2/m2 for
men.
Results Five of 16 patients (31 %) were men; median age,
60 years. Forty-four percent (7/16) of patients were
sarcopenic. Fatigue, anemia, hyperglycemia, and hyperlip-
idemia were common. Baseline sarcopenia and body com-
position did not correlate with worse toxicity or treatment
outcome. However, there was a trend for greater loss of
adipose area (p=0.07), fat mass (p=0.09), and adipose index
(p=0.07) for patients with grade 3 or 4 toxicities versus those
with grade 1 and 2 side effects.
Conclusion Patients with higher grade toxicities tended to
lose more body fat, suggesting a possible end-organ meta-
bolic effect of temsirolimus. These observations merit ex-
ploration in a larger cohort of patients.
Keywords Temsirolimus . Body composition . Sarcopenia .
Toxicity
1 Introduction
Cancer treatment and cure remain a challenge to modern
medicine; but recently, we have witnessed significant prog-
ress, especially in long-term disease control, transforming
some cancer subtypes to a more chronic disease [1, 2]. More
recently, there is an effort to personalize cancer treatment
based on molecular aspects of the tumor, as well as the host
characteristics [3, 4].
Body weight and body composition (fat and leanmass), are
other features that play an important role in cancer etiology,
prognosis, and treatment outcome [5, 6]. Body composition
may also have significant impact on treatment-related toxic-
ities, mainly for patients who are obese and/or have depletion
of muscle mass, i.e., sarcopenia [5]. Sarcopenia may affect
outcome by changing drug distribution and metabolism [7–9]
and hence, personalizing and optimizing treatment might be
enhanced by body composition measurements.
Cancer patients are at increased risk for sarcopenia be-
cause of the wasting syndrome (cachexia) that is a feature of
many malignancies, having an incidence between 50–90 %
of untreated patients [10]. Pancreatic and gastric malignan-
cies are most frequently associated with weight loss greater
than 5 % [11].
Temsirolimus is a mammalian target of rapamycin (mTor)
inhibitor that has been approved by the US Food and Drug
Administration for treatment of renal cell carcinoma [12]. Be-
cause it affects the phosphatidylinositol-3-kinase (PIK3)/AKT/
mTor axis, it is conceivable that it may be useful in other tumors
as well. Side effects including weight loss have been noted [12]
and we have anecdotally observed failure to thrive in occasional
patients with tumor regression. The mTor inhibition caused by
temsirolimus affects other physiological processes linked to the
PIK3/mTor/AKT pathway such as glucose, lipid, and protein
metabolism. Pre-clinical data demonstrates that a catabolic state
is associated with mTor inhibition [13–16], and relevant side
effects seen with temsirolimus include hyperlipidemia and
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mucositis [17]. We therefore sought to analyze the association
between body composition, including sarcopenia, and temsiroli-
mus therapy.
2 Patients and methods
Twenty-six patients with documented advanced solid tumors
(gynecological malignancies, non-small cell lung cancers,
colorectal cancers, and others) who presented to the Clinical
Center for Targeted Therapy (Phase I Clinic) at M.D. Ander-
son Cancer Center (MDACC) and who were enrolled on
temsirolimus trial were studied. Inclusion criteria for the
temsirolimus protocol were evaluable tumor(s) with docu-
mented PIK3 mutation and/or PTEN loss; patients with
advanced/metastatic cancer that was refractory or relapsed
after standard therapy, or had no standard therapy that im-
proved survival by at least 3 months (unless temsirolimus
was the standard treatment for that disease); creatinine ≤3×
upper limit of normal (ULN); absolute neutrophil count
≥1,000/mL; platelets ≥50,000/mL; and bilirubin ≤3.0 g/dL
or ≤5 ULN if liver metastasis is present. Patients had to be off
other anti-tumor agents for at least five half-lives or 4 weeks
from the last day of treatment, whichever was shorter. For
cytotoxic therapies, patients must have been at least 3 weeks
off treatment. Patients could not be receiving any other
experimental anti-tumor drugs. Exclusion criteria: pregnant
or lactating women; known hypersensitivity to any of the
components or metabolites of the drug products; and major
surgery within 30 days prior to entering the study. Patients on
inhibitors or inducers of CYP3A4 metabolism had the inhib-
itors or inducers stopped unless clinically contraindicated.
The guidelines of the Internal Review Board at MDACC
were followed for the temsirolimus protocol and the current
body composition study.
2.1 Computed tomography imaging
Computed tomography (CT) images were performed at base-
line (within 30 days before treatment) and were repeated
every 2 cycles (about 8 weeks). Each cycle consisted of
weekly 25 mg of temsirolimus intravenously for 4 weeks.
The plan was that each patient would receive two treatment
cycles before restaging. Tumor response was determined by
Response Evaluation Criteria in Solid Tumors (RECIST),
version 1.0. [18]
2.2 Demographic data
Demographic data (age, gender, cancer diagnosis, height,
and weight) was collected from electronic medical records.
Body weight was assessed at initiation of treatment and after
two treatment cycles.
2.3 Toxicity data
Toxicity assessment was determined by review of elec-
tronic medical records and graded based on the Common
Terminology Criteria for Adverse Events version 3.0. [19].
Patients were divided into two groups based on toxicity
grade (grades 1–2 versus 3–4), since grade 3 or 4 toxic-
ities likely would require dose reductions and treatment
interruptions.
2.4 Laboratory data
Laboratory data was collected at baseline (within 7 days
before the first treatment dose) and at the end of cycle
two, which was within 7 days of the restaging scans.
Complete blood counts, electrolytes, glucose, liver, and
kidney profiles were accessed at baseline and at first
restaging; lipid panel was evaluated at least once during
the 8-week period.
2.5 Body composition assessments
Body mass index (BMI) was calculated with patient's weight
(in kilograms) divided by height (in square meters) [20].
Lean body mass was calculated using the validated method
described below.
Abdominal images at the level of the third lumbar verte-
bra (L3) were used for body composition analysis. The L3
CT cross-sectional image was chosen for analysis because it
contains the following muscles: psoas, erector spinae,
quadratus lumborum, transversus abdominis, rectus
abdominis, and the external and internal oblique muscles,
which together, are optimal for estimating lean body mass.
The use of the L3 as the landmark for body composition
analysis has been previously described and validated [21].
Muscle, intramuscular fat, subcutaneous fat, and visceral fat
were identified by a single assessor trained in the specific
anatomy of these tissues, demarcated using previously de-
scribed Hounsfield unit thresholds [22] and quantified with
sliceOmatic software, version 4.3 (TomoVision, Montreal,
QC, Canada). Lean body mass (LBM) and fat body mass
(FM) were estimated by the Mourtzakis et al. [23] formulae,
(LBM (kg)=0.30 × skeletal muscle at L3(cm2)+6.06 and FM
(kg)=0.042 × fat tissue at L3(cm2)+11.2), with demonstrated
reliability (r=0.94, p <0.0001 and r=0.88, p <0.0001, re-
spectively). Patients were considered sarcopenic if they had a
lumbar skeletal muscle index (skeletal muscle area at L3
divided by the height squared) lower than 38.5 cm2/m2 for
women and lower than 52.4 cm2/m2 for men, as previously
described [5]. Adipose index was determined by dividing
adipose tissue area at L3 by the squared height.
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2.6 Statistical analyses
Descriptive statistics were performed first to summarize
our data. Differences in categorical variables were de-
termined by Fisher's exact tests, where applicable. Dif-
ferences in continuous variables were determined by t
test or by the Mann–Whitney test, depending on the
normality of the data. Analyses were performed using
SPSS v. 19.0 (SPSS, Chicago, IL).
3 Results
3.1 Demography
From the initial 26 individuals, 17 patients (65 %) had
restaging after 2 cycles and had body composition evaluated
by the tomography method above. The remaining nine pa-
tients were not able to complete two treatment cycles; eight
due to early progression, and one patient died in a car
accident before restaging. One of the 17 patients had artifacts
on imaging that compromised the evaluation. Therefore, the
final study sample was 16 patients (11 women and five men).
Median age was 60 years (range, 36–71 years). The most
common tumor types were gynecological malignancies. De-
mographic data is summarized in Table 1.
3.2 Anthropometric data
At baseline, two (12 %) patients were underweight (BMI
<18.5 kg/m2), 10 (63 %) patients had normal weight
(BMI=18.5–24.9 kg/m2), one (6 %) patient was overweight
(BMI=25–29.9 kg/m2), and three (19 %) patients were obese
(BMI ≥30 kg/m2). There were no significant changes in
weight (p=0.87) and BMI (p=0.73) after two treatment cy-
cles. The mean time between CT scans to assess body com-
position was 9 weeks. No significant changes in the median
values of body composition parameters were identified; skel-
etal muscle area (SMA) (p=0.57), LBM (p=0.56), skeletal
muscle index (SMI) (p=0.36), adipose area (AA) (p=0.65),
FM (p=0.67), and adipose index (AI) (p=0.60).
Sarcopenia (SMI <38.5 cm2/m2 for women and
<52.4 cm2/m2 for men) was a frequent finding, as is expected
in cancer patients. There was no significant increase
(p=0.72) in the prevalence of sarcopenia at baseline (7/16,
44 %) versus after two treatment cycles (9/16, 56 %). All
patients that were sarcopenic at baseline remained
sarcopenic after treatment. Two patients became sarcopenic
after treatment—one man (SMIbaseline=60.1 cm
2/m2 and
SMIafter treatment=48.1 cm
2/m2) and one woman
(SMIbaseline=39.8 cm
2/m2 and SMIafter treatment=35.7-
cm2/m2). There was no difference in the median age between
the sarcopenic and non-sarcopenic groups (63 and 62
years, p=0.75).
3.3 Toxicities
The most common toxicities, at least possibly drug-related,
were fatigue (16/16, 100 %), anemia (16/16, 100 %), hypergly-
cemia (13/16, 81 %), and hypercholesterolemia (12/16, 75 %).
The great majority of the toxicities were grade 1 or 2 (100/111,
90 %). Anemia, thrombocytopenia, leucopenia/neutropenia,
and aspartate aminotransferase/alanine aminotransferase eleva-
tions were the only grade 3 or 4 toxicities.
3.3.1 Baseline sarcopenia and toxicity
Baseline sarcopenia (i.e., SMI <38.5 cm2/m2 for women and
<52.4 cm2/m2 for men) did not correlate with toxicity profile;
the median number of toxicities per patient was seven (range
5–9) for both sarcopenic and non-sarcopenic patients
(p=0.74). Grade 3 or 4 toxicities occurred in 3/7 sarcopenic
patients and 3/9 non-sarcopenic patients at baseline.
3.3.2 Baseline body composition and toxicity
Median values for body composition parameters at baseline
among patients with grade 1 or 2 toxicity versus 3 or 4 were
not significantly different (Table 2).
Table 1 Demographic characteristics of patients treated with
temsirolimus, and assessable for body composition
Characteristics Number
Gender
Women (%) 11 (69)
Men (%) 5 (31)
Age, years
Median (range) 60 (36–71)
Performance status (ECOG)
<2 (%) 15 (94)
≥2 (%) 1 (6)
Cancer diagnoses
Endometrial (%) 4 (25)
Ovarian (%) 3 (18)
Cervical (%) 2 (12)
Non-small cell, lung (%) 2 (12)
Colorectal (%) 2 (12)
Melanoma (%) 1 (6)
Squamous cell, anus (%) 1 (6)
Neuroendocrine (%) 1 (6)
Number of prior therapeutic regimens
Median (range) 4 (1–11)
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3.3.3 Body composition changes and toxicity after two
treatment cycles
The body composition changes were estimated as a delta
function:
Deltabodycompositionparameter ¼ bodycompositionparameterafter treatment
−bodycompositionparameterbaseline
Changes in body composition parameters after two treat-
ment cycles (about 8 weeks) were not significantly different
between the grade 1 or 2 toxicity group and the grade 3 or 4
toxicity group; however, there was a trend for a greater loss
of adipose area (p=0.07), fat mass (p=0.09), and adipose
index (p=0.07) for patients with grade 3 or 4 toxicity versus
patients with grade 1 or 2 (Table 3).
3.4 Therapy response
3.4.1 Baseline sarcopenia and response
Eleven patients had stable disease or partial response
(SD/PR) and five patients had progressive disease (PD) after
2 months. Three out of seven sarcopenic (43 %) patients at
baseline had PD after 2 months versus two out of nine non-
sarcopenic (23 %) patients (p=0.60). The average best re-
sponse by RECIST criteria, after 2 months, was 18 % in-
crease in tumor measurement for baseline sarcopenic pa-
tients and 5 % increase for baseline non-sarcopenic patients
(p=0.20) (Fig. 1).
3.4.2 Baseline body composition and response
Median values of baseline body composition parameters
were not significantly different for patients with SD/PR
versus those with PD and are summarized in Table 2.
3.4.3 Body composition changes after two treatment cycles
and response
Body composition parameters did not change significantly
after 2 months when comparing the SD/PR group and the PD
group (Table 3).
3.5 Toxicity and therapy response
Four (36 %) out of 11 patients with SD/PR had grade 3 or 4
toxicity versus two (40 %) out of five patients with PD
(p=1.00).
4 Discussion
Temsirolimus is an antineoplastic agent, which acts predom-
inantly by inhibiting the mTor kinase. It has a gastrointestinal
toxicity profile that includes mucositis, nausea, and anorexia.
Therefore, it would be expected that patients on treatment
with this agent could lose weight [12]. Temsirolimus also
effects lipid profile and metabolism [17] and all these mech-
anisms may account for the fact that about 19 % of patients
showed significant weight loss [12].
The mTor pathway is a key signaling for cell proliferation
making it an important target for cancer therapy [12, 24].
However, there are other physiological processes that also
depend on this pathway, such as protein synthesis, insulin
signaling, and lipid metabolism [15, 25], and all of these
might impact body composition. Pre-clinical data have dem-
onstrated that activation of PIK3/mTor/AKT pathway plays
an important role on muscle skeletal trophism, inducing
hypertrophism, inhibiting muscle atrophy, and inducing lipo-
genesis [13, 14]. In animal models, chronic treatment with
rapamycin caused glucose intolerance and reduced the number
Table 2 Body composition parameters at baseline and relation to toxicity and to therapy response by RECIST criteria after two treatment cycles
Median (IQR) Toxicity Response
Grade 1 or 2 toxicity Grade 3 or 4 toxicity p Value SD/PR PD p Value
Total n=16 n=10 n=6 n=11 n=5
Weight(kg) 65.8 (23.5) 54.9 (27.3) 0.59 62.7 (23.3) 59.1 (29.1) 0.46
BMI (kg/m2) 21.5 (9.9) 20.5 (4.4) 0.28 21.2 (9.9) 21.2 (3.3) 0.53
SMA (cm2) 128.1 (46) 107.4 (32.3) 0.28 125.5 (30.4) 103.5 (48.7) 0.69
LBM (kg) 44.5 (13.8) 38.3 (9.7) 0.28 43.7 (9.1) 37.1 (14.6) 0.69
SMI (cm2/m2) 45.1 (13.9) 39.7 (3.8) 0.59 44.2 (12.5) 39.8 (5.2) 0.46
AA (cm2) 149.3 (217.3) 166.7 (216.6) 0.66 164.4 (242.8) 147.3 (132.9) 0.61
FM (kg) 17.5 (9.1) 18.2 (9.1) 0.63 18.1 (10.2) 17.4 (5.5) 0.57
AI (cm2/m2) 48.4 (78.0) 58.3 (82.5) 0.87 49.1 (83.6) 47.7 (34.1) 0.57
AA adipose area, AI adipose index, FM fat mass, IQR interquartile range, LBM lean body mass, PD: progressive disease, PR partial response, SD
stable disease, SMA skeletal muscle area, SMI skeletal muscle index
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of adipose cells, impairing lipid deposition on adipose tissue
and culminating in elevated plasma levels of triglycerides [16].
In the clinical setting, hyperlipidemia and hyperglycemia are
features of temsirolimus and other mTor inhibitors-side effects
[12]. Recently, Antoun et al. [26] demonstrated that muscle
loss is specifically exacerbated by sorafenib in patients with
renal cell carcinoma, possibly related to the downstream inhi-
bition of PIK3/AKT/mTor pathway, confirming the pre-
clinical models.
Our analyses did not show a significant overall decrease
in weight, BMI, or other body composition parameters in the
first 2 months, which could be explained by the fact that all
patients with anorexia, nausea, and/or mucositis had only
grade 1 or 2 toxicities, and/or might be because the follow-up
of our study was not long enough to detect such changes. The
small number of patients might also preclude finding statis-
tically significant changes.
Sarcopenia, as reflected by SMI, was found in 7/16 pa-
tients (44 %) in our study population (3/11 women and 4/5
men) in concordance with other studies. Our previous report
showed sarcopenia in 51 % in a group of 104 patients with
diverse solid tumors referred to our Phase I Clinic [27]. Tan
et al. [28] found a prevalence of sarcopenia in 56 % of 111
patients with advanced pancreatic cancer, and Prado et al. [7]
found sarcopenia in 25 % of women with metastatic breast
cancer.
Previous reports have shown that sarcopenia and low lean
body mass had a significant impact on toxicity, more specif-
ically in the incidence of grade 3 or 4 toxicities, for patients
treated with chemotherapy (5-fluoracil, cyclophosphamide,
methotrexate, and capecitabine) or target agents such as
sorafenib [7–9, 29]. From our analyses, patients who were
sarcopenic at baseline did not have increase in grade 3 or 4
toxicities. Patients who developed grade 3 or 4 toxicities had
a lower SMI at baseline, but the difference was not statisti-
cally significant when compared to the group with grade 1 or
2 toxicities.
After treatment, individual body composition variables
did not change in a statistically significant fashion. However,
there was a trend for a greater decrease of body fat parame-
ters after treatment in patients with grade 3 or for toxicity
(p=0.07). These results may suggest that patients who lose
body fat are more vulnerable to grade 3 or 4 temsirolimus-
related toxicities. Alternatively, developing grade 3 or 4
toxicities and a decrease in fat mass may be related to greater
end-organ impact or higher blood levels of temsirolimus in
these patients. Recently, several studies have addressed the
relationship between body composition and targeted therapy,
especially anti-angiogenesis agents. Renal carcinomas are of
Table 3 Body composition changes after two treatment cycles and relation with toxicity and therapy response per RECIST criteria
Variable, median (IQR) Toxicity Response
Grade 1/2 Grade 3/4 p Value SD/PR PD p Value
n=16 n=10 n=6 n=11 n=5
Δ Weight (kg) −0.8 (5.4) −1.5 (6.2) 0.79 −0.8 (5.3) −0.8 (5.9) 0.78
Δ BMI (kg/m2) −0.4 (1.9) −0.6 (2.4) 0.87 −0.4 (1.9) −0.3 (2.1) 0.74
Δ SMA (cm2) −3.5 (11.4) −6.6 (16.0) 0.66 −5.0 (17.0) 0.9 (13.8) 0.31
Δ LBM (kg) −1.1 (3.4) −2.0 (4.8) 0.66 −1.5 (5.1) 0.3 (4.2) 0.31
Δ SMI (cm2/m2) −1.4 (3.9) −2.2 (6.5) 0.66 −2.0 (5.6) 0.4 (4.8) 0.34
Δ AA (cm2) −12.3 (52.0) −32.8 (30.2) 0.07 −18.2 (44.5) −30.4 (31.9) 0.33
Δ FM (kg) −0.6 (2.2) −1.4 (1.2) 0.09 −0.8 (1.9) −1.3 (1.4) 0.33
Δ AI (cm2/m2) −4.5 (18.2) −13.5 (11.9) 0.07 −6.3 (16.9) −10.9 (10.1) 0.40
Δ refers to median value of each body composition parameter after treatment − median value before treatment
AA adipose area, AI adipose index, FM fat mass, IQR interquartile range, LBM lean body mass, PD progressive disease, PR partial response, SMA
skeletal muscle area, SD stable disease, SMI skeletal muscle index
Fig. 1 Sarcopenia data and response to RECIST
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special interest because obesity may be a known risk factor
for development of this malignancy [30], and anti-
angiogenesis agents, as well as mTor inhibitors, are currently
the back-bone of standard therapy. Body fat content, until
recently, demonstrated very little evidence of impacting sur-
vival and toxicity [26]. However, Steffens et al. [31, 32]
showed that increased body fat was related with longer
survival for patients with renal cell carcinoma treated with
VEGF-targeted therapy. On the other hand, Ladoire et al.
[32, 33] showed that increase in visceral fat was correlated
with shorter overall survival in patients with renal cell car-
cinoma. Therefore, our understanding of the complex inter-
action between cancer and the host's characteristics is incom-
plete, but may be especially relevant to targeted agents with
metabolic effects.
There are several limitations to our study. These are
preliminary findings of a pilot study. The low number of
patients and the short follow-up period preclude a robust
statistical analysis. In conclusion, we could not demonstrate
an impact of temsirolimus on skeletal muscle content like
others have shown for other targeted agents [26], however
our results suggest that patients treated with an mTor inhib-
itor who develop grade 3 or 4 toxicities tend to lose more
body fat content than those with only grade 1 or 2 toxicities.
Our observations are hypothesis generating and merit explo-
ration in a larger cohort of patients.
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